Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from OncoSil Medical Ltd ( (AU:OSL) ).
OncoSil Medical has completed the first treatment using its OncoSil™ device at Acibadem Maslak Hospital in Istanbul, marking a key milestone in its international expansion strategy. Türkiye, with around 8,500 new pancreatic cancer cases annually and a sophisticated, fast-adopting private healthcare sector, is seen as a strategically important growth market, and establishing clinical use at a flagship institution within the Acibadem Health Group is expected to build awareness, clinical momentum and broader regional uptake of the therapy for patients with unresectable locally advanced pancreatic cancer.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company specialising in interventional oncology, focused on developing localised radiation therapies for unresectable locally advanced pancreatic cancer. Its lead product, the OncoSil™ device, delivers targeted Phosphorous-32 (32P) microparticles directly into pancreatic tumours alongside chemotherapy, enabling higher local radiation doses while sparing surrounding organs. The device holds CE marking, breakthrough device designation in Europe and the US, and is approved in more than 30 countries, with commercial use already established across several European markets, Turkey, Israel and the UK.
Average Trading Volume: 21,988
Technical Sentiment Signal: Sell
Current Market Cap: A$16.44M
See more data about OSL stock on TipRanks’ Stock Analysis page.